Metropolitan Life Insurance CO Fennec Pharmaceuticals Inc. Transaction History

Metropolitan Life Insurance CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 10, 2023	BUY	$7.27 - $9.82 $7,291 - $9,849	1,003 New	1,003 $8,000
Q3 2020 Nov 13, 2020	SELL	$5.19 - $10.17 $40,606 - $79,570	-7,824 Closed	0 $0
Q2 2020 Jun 26, 2023	BUY	$5.43 - $9.39 $42,484 - $73,467	7,824 New	7,824 $65,000
Q2 2020 Mar 30, 2023	BUY	$5.43 - $9.39 $42,484 - $73,467	7,824 New	7,824 $65,000
Q2 2020 Aug 14, 2020	BUY	$5.43 - $9.39 $42,484 - $73,467	7,824 New	7,824 $65,000

14.7M

10K

83.8K

Ticker FENC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,067,300
Market Cap $169M
Description
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec...

Get notified when there are updates to the investment portfolio of Metropolitan Life Insurance CO, based on Form 13F filings with the SEC.

Stay updated on Metropolitan Life Insurance CO with notifications on news.